A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

Trial Profile

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs INT 230-6 (Primary)
  • Indications Breast cancer; Colon cancer; Glioblastoma; Head and neck cancer; Liver cancer; Lung cancer; Lymphoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms IT01
  • Sponsors Intensity Therapeutics
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 1 Jan 2020 to 1 Aug 2020.
    • 07 Aug 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
    • 30 May 2017 According to an Intensity Therapeutics media release, the first patient successfully received treatment with INT230-6.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top